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Abstract
Background—Women living with HIV infection are at higher risk for cervical cancer, an AIDS-
defining diagnosis. We examined the prevalence of cervical cancer and sexually transmitted 
disease (STD) screening among human immunodeficiency virus (HIV)-infected women and 
factors associated with the receipt of Papanicolaou (Pap) tests.
Methods—We did a cross-sectional analysis of weighted data from a sample of HIV-infected 
adults receiving outpatient medical care. We used matched interview (report of Pap test) and 
medical record data (STD screenings) from HIV-infected women. We performed logistic 
regression to compute adjusted prevalence ratios and 95% confidence intervals for the association 
between demographic, behavioral, and clinical factors and receipt of Pap tests among HIV-infected 
women.
Results—Data were available for 2,270 women, who represent 112,894 HIV-infected women; 
62% were African American, 17% were Hispanic/Latina, and 18% were white. Most (78%) 
reported having a Pap test in the past year. Among sexually active women (n= 1234), 20% 
reported sex without condoms, 27% were screened for gonorrhea, and 29% were screened for 
chlamydia. Being screened for STDs was less likely among women who did not have a Pap test in 
the past year (adjusted prevalence ratios 0.82, 95% confidence interval 0.77–0.87). Women who 
were ≥50 years of age and reported income above federal poverty level, no sexual activity, 
depression, no HIV care from an obstetrician/gynecologist, and no documented STD tests, were 
less likely to report a Pap test (p < 0.05).
Conclusions—Screening for cervical cancer and STDs among HIV-infected women is 
suboptimal. Clinical visits for Pap tests are an important opportunity for HIV-infected sexually 
active women to also receive STD screenings and counseling regarding condoms.
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An estimated 1.2 million people in the United States are living with human 
immunodeficiency virus (HIV) infection, and 296,000 (24.6%) of these are women.1 
Compared with HIV-uninfected women, HIV-infected women have a higher prevalence of 
human papilloma virus (HPV) infection,2 are more likely to have high-risk oncogenic HPV 
subtypes (which are associated with 70% of cervical cancers),3 and are more likely to 
develop invasive cervical cancer.4 Level of immunosuppression, measured by CD4+ T-
lymphocyte cell (CD4) count, is also associated with incidence of cervical cytologic 
abnormalities, with lower CD4 counts being associated with an increased risk of cervical 
abnormalities, including cancer.5 Invasive cervical cancer has been an acquired immune 
deficiency syndrome (AIDS)-defining diagnosis since 1993,6 and national recommendations 
for more frequent Papanicolaou (Pap) test screenings for HIV-infected women have been in 
place since 1995. Current clinical guidelines state that HIV-infected women should be 
screened for cervical cancer twice within the first year after HIV diagnosis, and if the results 
are normal, annually thereafter.7 Yet previous reports show that between 19% and 47% of 
HIV-infected women did not report having the recommended Pap test in the previous 12–18 
months.8, 9 More recent analyses suggest that longer intervals for Pap tests may be 
appropriate for some HIV-infected women with serial negative Pap tests, based on low rates 
of high-grade cervical intraepithelial neoplasia.10, 11
The pelvic exam that occurs at the time of the Pap test is also an opportunity to screen for 
other sexually transmitted diseases (STDs) that may be diagnosed by collection of vaginal or 
cervical fluid. The Centers for Disease Control and Prevention (CDC) recommends at least 
annual screening for gonorrhea, chlamydia, and syphilis for all sexually active HIV-positive 
persons.12 Therefore, determining the factors associated with receiving a Pap test may help 
inform more effective preventive services interventions for sexually active HIV-infected 
women.
Our objectives were to describe the prevalence of reported Pap tests and clinical 
documentation of STD screening tests in a diverse, national, probability sample of HIV-
infected women and to examine the sociodemographic, behavioral, and clinical factors 
associated with not receiving Pap test screening in the previous year. This analysis builds 
upon previously published summaries8, 9 of reported Pap test frequency by including 
contextual variables, such as sex without a condom, and STD screening, both of which have 
implications for exposure to HPV and the importance of cervical cancer screenings. This 
analysis also includes clinical information, including documented antiretroviral therapy 
(ART) prescriptions, plasma HIV RNA viral load, Pap tests received at the HIV care 
provider’s facility, and viral suppression status abstracted from medical records. These 
analyses can inform the development of interventions to strengthen gynecologic preventive 
services, including Pap and STD screenings for HIV-infected women.
Methods
The Medical Monitoring Project (MMP) is an ongoing HIV surveillance system with a 
three-stage sampling design to obtain nationally representative, annual cross-sectional 
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samples of HIV-infected adults receiving outpatient medical care for HIV in the United 
States.13 For the 2009 and 2010 data collection cycles, U.S. states and territories were 
sampled, followed by facilities providing HIV care, and finally adults aged 18 years or older 
receiving at least one medical HIV care visit in participating facilities between January and 
April in 2009 or 2010. For state and territory samples, probability of selection was 
proportionate to AIDS prevalence; for provider samples, probability of selection was 
proportionate to HIV-infected patient census. Data were collected through face-to-face 
interviews and medical record abstractions from June 2009 to May 2011. The following 
surveillance jurisdictions participated in MMP: California, Chicago (Illinois), Delaware, 
Florida, Georgia, Houston (Texas), Illinois, Indiana, Los Angeles County (California), 
Michigan, Mississippi, New Jersey, New York, New York City (New York), North Carolina, 
Oregon, Pennsylvania, Philadelphia (Pennsylvania), Puerto Rico, San Francisco (California), 
Texas, Virginia, and Washington.
The number of facilities sampled in 2009 and 2010 was 603 and 582, respectively. Among 
those sampled, 461 and 474 facilities participated, resulting in a facility response rate of 
76% and 81% for 2009 and 2010, respectively. Most of the HIV care facilities sampled were 
private practices (60%), followed by hospital-based facilities (30%) and community health 
centers (19%). The remainder were clinical research facilities (10%), state or local health 
department clinics (5%), community-based service organizations (4%), and Veterans 
Administration facilities (4%).
Of nearly 9,400 persons sampled per data collection year, completed interview and linked 
medical record abstraction data were available for 4,217 in 2009 and 4,474 in 2010. The 
adjusted patient response rate was 51% and 50% in 2009 and 2010, respectively; the average 
combined adjusted patient response rate was 51% for the two data collection years. Also, 
using information collected on all sampled facilities and 88% of sampled patients, we 
conducted an analysis to compare respondents and nonrespondents. Data were then 
weighted to adjust for nonresponse by using predictors of response, including facility size, 
facility type (public or private), patient race and ethnicity, time since HIV diagnosis, and age 
group. After weighting for probability of selection and nonresponse, the sample of 8,691 
MMP participants were estimated to represent an average population of 431,915HIV-
infected adults receiving medical care in the United States during the study period.
The CDC has determined MMP to be a nonresearch public health surveillance activity to 
guide disease control programs and policy, and MMP was approved by CDC.14 Several 
participating states, territories, and facilities obtained local internal review board approval 
and informed consent from study participants as required by local entities. Eligible persons 
were invited to participate on a voluntary basis; participants could decline to answer any 
question or could stop study participation at any time.
There were 2,270 participants who met inclusion criteria: (1) were born and self-identified 
as a female; (2) were diagnosed as HIV-positive for at least one year; (3) responded yes or 
no to the Pap test question during the interview; and (4) completed a face-to-face interview 
and had medical record data abstracted from records during an outpatient visit or 
hospitalization during the 12 months before interview.
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The primary outcome variable was receipt of a Pap test in the past year. All women were 
asked, “During the past 12 months, have you had a Pap smear?” Women who responded yes 
were categorized as reporting a Pap test in the past year; some Pap tests may have been 
obtained at a facility other than the HIV care facility. Sociodemographic variables included 
were age at interview in years, race/ethnicity, education, time since HIV diagnosis in years, 
and foreign birth. Participants were asked selected questions to determine if the following 
applied to them during the past year: had a lapse in continuous health or insurance coverage, 
lived at or below poverty level, were incarcerated, experienced homeless, and/or had any 
depression. The number and percentage of women in the United States meeting current 
poverty guidelines was determined using the U.S. Department of Health and Human 
Services poverty guidelines that corresponded to the year of interview.15 Women were 
categorized as homeless if they lacked a fixed, regular, adequate nighttime residence (per 
Stewart B. McKinney Homeless Assistance Act, 42 U.S.C. §11301, et seq; 1987). 
Determination of depression in the past year prior to interview was categorized as no 
depression, other depression, or major depression, based on the algorithm from Kroenke.16
Reported behaviors in the past year included oral or vaginal sex without a condom with a 
male partner; binge drinking (four or more alcoholic drinks within one day); current 
smoking; and any drug use (noninjection and injection drugs), defined as drugs not used for 
medical purposes. The use of selected health care services was assessed by self-reported 
information and clinical data abstracted from medical records for the year prior to interview. 
Self-reported data indicating use of health care services in the past year included one-on-one 
conversations with a health care provider about ways to prevent HIV and STD transmission 
and receipt of HIV care from an obstetrician or gynecologist (OB/GYN).
Clinical variables (medical record abstraction data)
Clinical data were abstracted from participants’ medical records for the year prior to 
interview and included plasma HIV RNA viral load (most recent viral suppression was 
defined as having a most recent HIV viral load result of undetectable or <200 copies/mL); 
prescription of ART; documentation of three or more CD4+ T-lymphocyte or HIV viral load 
tests; documentation of testing for chlamydia or gonorrhea at any anatomical site 
(pharyngeal, anorectal, urethral, cervical, lymph node, ocular), or of the urine, or not 
specified, and syphilis screening; and disease stage per CDC criteria [Stage 1: No AIDS and 
nadir CD4 ≥500 cells/µL (or CD4% ‡29); Stage 2: No AIDS and nadir CD4 200–499 cells/ 
µL (or CD4% 14- <29); and Stage 3: AIDS or nadir CD4 0–199 cells/µL (or CD4% <14)]. 
Medical charts were also reviewed to determine numbers of documented Pap tests obtained 
at the HIV care facility.
We examined the unweighted frequencies and weighted percentages of demographic and 
behavioral characteristics, health care services received, and clinical status indicators for 
HIV-infected women receiving medical care. We then calculated estimates of reported 
receipt of Pap tests in the past year by available variables. Modified Rao-Scott chi-squared 
tests were used to measure the bivariate association between each factor and receipt of a Pap 
test in the year prior to interview. We calculated unadjusted prevalence ratios (PRs) with 
95% confidence intervals (CIs) in the HIV-infected population using logistic regression with 
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predicted marginal means. We used a multivariable logistic regression model with a 
significance level of <0.05 to determine the adjusted prevalence ratios (aPRs) for not 
receiving cervical cancer screening. We selected certain a priori variables, which were 
included in the initial model, and used a backward selection method to build the model and 
removed each factor from the full model that was not significant at p < 0.05. We also 
assessed two-way interactions between variables, with a cutoff of p < 0.05. The Hosmer- 
Lemeshow test of goodness of fit was performed to assess model stability.
Additional analyses were completed to compare any documentation in the medical records 
of receipt of Pap tests at the HIV care facility and the self-reported Pap tests received in the 
past year. The kappa statistic and the percentage agreement were computed to assess the 
agreement between the two estimates. A subanalysis of sexually active HIV-infected women 
in care was completed to examine the documentation of screening from the medical records 
for STDs (gonorrhea, chlamydia, and syphilis), stratified by receipt of Pap tests. All 
weighted analyses were performed using SURVEY procedures in SAS 9.3 (SAS Institute) 
and SAS-callable SUDAAN 10.0.1 (RTI International). The SAS and SUDAAN procedures 
included sampling weights and strata and cluster information to account for the complex 
survey design of MMP.
Results
Of the 8,691 participants in the 2009–2010 MMP sample, 2,321 were female. Of the 2,321 
female MMP participants, 51 (2.2%) women did not meet the criteria for inclusion in this 
analysis: 18 did not respond to the Pap test question; 31 were diagnosed less than one year 
before the interview, and 2 had an unknown date of HIV diagnosis. A total of 2,270 women 
were included in this analysis, representing 112,894 (CI 96,368–129,421) HIV-infected 
women receiving medical care in the United States.
The majority (72%) of women were aged 40 years and older at the time of the interview, 
were black or African American (62%), were diagnosed with HIV at least 10 years before 
the interview (53%), lived at or below poverty level (63%), and had continuous health or 
insurance coverage (72%). Table 1 has full details regarding the demographics and key 
behavioral findings of the analytic sample.
Over half (51%) of women reported some sexual activity with a male partner; 20% reported 
having sex without condoms. Less than half of all women had medical record evidence of 
being screened separately for gonorrhea (27%), chlamydia (29%), and syphilis (48%); only 
19% had evidence of screening for all three—gonorrhea, chlamydia, and syphilis in the past 
12 months. Less than 20% of women reported any drug use, and 41% currently smoked 
(data not shown). An estimated 31% reported depression symptoms.
In all, 78% of women reported receiving a Pap test and 77% reported receiving a pelvic 
examination in the 12 months before the interview (results not shown). Most women (70%) 
had medical record documentation of three or more CD4 or viral load tests in the previous 
12 months (indicating regular HIV care), 88% were prescribed ART, and 69% were virally 
suppressed based on their most recent viral load. Most of the women had a diagnosis of 
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AIDS (67%) and reported either having had a one-on-one conversation(s) with a health care 
provider about HIV and STD prevention (49%) or HIV care from an OB/GYN (21%).
Results from the multivariate analysis indicated that women with the following 
characteristics and behaviors were less likely to have reported having had a Pap test in the 
past year: aged 50 years or older (aPR 0.88, 95% CI 0.81–0.96) compared with those aged 
18–29 years; with income above federal poverty level (aPR 0.94, CI 0.90–0.99); who had no 
sexual activity in the past 12 months (aPR 0.93, CI 0.87– 0.98) compared with those who 
had any protected sex; and who reported any drug use in the past 12 months (aPR 0.91, CI 
0.83–1.00). In addition, women who reported the following in the 12 months prior to 
interview were less likely to report a Pap smear during that period: depression other than 
major depression (aPR 0.88, CI 0.80–0.96) compared with women with no depression; 
having had conversations with a health care provider about HIV (aPR 0.94, CI 0.89–1.00); 
not having received HIV care from an OB/GYN (aPR 0.80, CI 0.75–0.85). Finally, women 
without medical record documentation of three or more CD4 or viral load tests and no 
medical evidence of being tested for gonorrhea, chlamydia, and syphilis in the past year 
were less likely to report having received a Pap smear (aPR 0.91, CI 0.86–0.96; and aPR 
0.82, CI 0.77–0.87, respectively) (Table 2).
Self-reported data on Pap testing were compared with medical record Pap testing 
documentation at the HIV care facility. Although 78% (1,771/2,270) of women reported that 
they had a Pap test in the past year, only 795/1,771 (45%; CI 40.01–49.59) had medical 
documentation of receiving cervical cancer screening at the HIV care facility in the previous 
12 months. The percentage positive agreement was 0.51, with a Kappa statistic = 0.20 (CI 
0.17–0.24). Of the 1,234 sexually active, HIV-infected women, women who had medical 
documentation of gonorrhea, chlamydia, and syphilis screening in the past year were 2.7 
times as likely to report having had a Pap test compared with those who did not have one in 
the past year (Fig. 1; last bar on chart).
Discussion
Screening for cervical cancer and STDs was suboptimal for our sample of HIV-infected 
women, whose frequency of documented CD4 count measures are consistent with them 
having regular HIV care clinical visits. These HIV care visits were missed opportunities for 
Pap and STD preventive screening services and sexual health counseling with women. Our 
findings suggest that Pap tests and STD screening services should be strengthened among 
both women’s health providers and HIV care providers to ensure optimal health outcomes 
for women living with HIV. Clinical visits for Pap tests are an important opportunity for 
sexually active HIV-infected women to also receive reinforced messages about condom use 
during sex for prevention of ongoing HIV transmission and about prevention of an 
unplanned pregnancy.18
Women were more likely to have STD screenings if they reported having a Pap test. Several 
factors in our study were associated with being less likely to report a Pap test. Previous 
studies have shown that factors associated with not having regular Pap screenings among 
HIV-infected women include being U.S. born, having a low CD4 count, and having received 
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a pelvic exam most recently at a place other than a woman’s usual source of HIV care.8, 19 
We believe that one of the challenges includes lack of Pap and STD screenings done by HIV 
primary care providers and lack of coordinated HIV and women’s health care at one location 
for HIV-infected women.19 Efforts to cross-train infectious disease providers (who 
disproportionately provide care for HIV-infected women) to perform Pap tests during visits 
or to partner with on-site OB/GYN providers might facilitate incorporation of recommended 
Pap screening, as well as STD screening, as part of a streamlined, user-friendly approach to 
routine care for women.
Women in our sample were even less likely to report Pap screening if they were age 50 or 
older, reported drug use or depression symptoms, or did not receive HIV care from an OB/
GYN. However, Pap screening recommendations are different if women have had 
hysterectomies (which may account for some of the reported lower Pap rates among older 
women), and women with drug use and depression history are more likely to have 
challenges with health care access to receive preventive Pap and STD screening services. 
Other studies support the increased performance of Pap tests among OB/GYN providers and 
other providers who routinely perform Pap tests.8, 19 Other national surveys of self-reported 
receipt of Pap tests among women in the general population have also shown that there is 
room for improvement toward the Healthy People 2020 goal (93% of females aged 21 to 65 
years should receive Pap screening)20 for all women. Although guidelines for the general 
population recommend Pap screening every three years for women aged 21–65 years 
without a hysterectomy, data from two national surveys found screening was suboptimal 
among U.S. women.21, 22 Although routine Pap test screenings are also suboptimal among 
the general population of U.S. HIV-uninfected women, the higher risk of cervical cytologic 
abnormalities among HIV-infected women underscores that providing regular Pap tests for 
prevention of invasive cervical cancer remains a priority.
Sexually active women in our sample also did not always receive the recommended annual 
STD screenings, and 20% of women were sexually active without condoms. CDC 
recommends routine screening for certain STDs (e.g., syphilis, gonorrhea, and chlamydia) at 
least annually for all sexually active, HIV-infected persons. In our study, syphilis screening 
rates were higher, likely because it is a blood test and can be obtained with routine CD4 and 
viral load labs. Still, the gap in Pap/STD screening services represents an area that may be 
strengthened by systematically linking STD screenings with Pap test visits, sending 
invitations to women as reminders to schedule a visit for screenings, and providing 
community education and outreach for women.23, 24 Ensuring that providers are aware of the 
most up-to-date screening recommendations may promote increased screenings for timely 
STD detection and treatment for HIV-infected women and encourage increased dialogue 
about sexual risk-reduction during routine clinical visits. These visits should include 
information and support for continued use of condoms and possibly discussions regarding 
pre-exposure prophylaxis to decrease the risk of HIV transmission, especially for HIV-
infected women who may be sexually active with uninfected partners.25
This analysis is subject to several limitations. First, the analysis was limited to HIV-infected 
women who received HIV care in MMP outpatient facilities. The results of this study are not 
generalizable to women who are not in HIV care, who are less likely to have had a recent 
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Pap test. Therefore, our results may have overestimated the receipt of Pap tests among all 
HIV-infected women. Second, the Pap test estimates are based on self-report; our data show 
that the number of women self-reporting Pap tests was higher than the number with a 
clinically documented Pap test at their HIV care facility.26 Clinical documentation 
abstracted for MMP is usually obtained from the sampled facilities where women receive 
HIV care, and some may have received care, including their Pap test, at other facilities. An 
ideal analysis would allow for a review of medically documented Pap tests at a facility that 
provides both HIV and gynecologic care for women. Third, our study is cross-sectional; 
whether the selected factors were causally associated with the receipt of Pap tests could not 
be assessed. Fourth, given the moderate response rate, there is a possibility of nonresponse 
bias. However, MMP used standard methods to mitigate potential nonresponse bias. Data 
were collected on facilities (HIV patient load) and all sampled patients (sex, age, race, 
length of time since diagnosis). We compared the characteristics of respondents and 
nonrespondents; based on the results of these analyses the data were weighted to minimize 
nonresponse bias.
Our study highlights suboptimal Pap and STD screening among HIV-infected women 
receiving medical care. Although HIV-infected women may experience barriers to accessing 
recommended preventive screenings, expanded health care coverage through the Affordable 
Care Act may present increased access for women and increased opportunities for providers 
to routinely screen (for reimbursement). 27, 28 Strategies to strengthen engagement of HIV-
infected women in recommended Pap and STD screenings and risk-reduction counseling are 
warranted in an effort to provide early detection and treatment and to decrease unintended 
sexual transmission of HIV and unplanned pregnancies (for sexually active women). 
Developing interventions that build upon increased access opportunities with community 
outreach and reminders for Pap/STD screenings are important additional strategies for 
women and an important part of providing care for women living with HIV infection.
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